1.15
1.71%
-0.02
After Hours:
1.15
Indaptus Therapeutics Inc stock is traded at $1.15, with a volume of 13,087.
It is down -1.71% in the last 24 hours and down -0.86% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$1.17
Open:
$1.17
24h Volume:
13,087
Relative Volume:
0.13
Market Cap:
$11.93M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-0.6534
EPS:
-1.76
Net Cash Flow:
$-13.41M
1W Performance:
-7.26%
1M Performance:
-0.86%
6M Performance:
-43.07%
1Y Performance:
-54.00%
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - The Manila Times
Indaptus Therapeutics partners with BeiGene for cancer study By Investing.com - Investing.com Canada
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment - Morningstar
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com
Indaptus Therapeutics Announces Clinical Supply Agreement - GlobeNewswire
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations - The Manila Times
Indaptus Therapeutics, Inc. Enters into Clinical Supply Agreement with Beigene Switzerland GmbH - Marketscreener.com
Provident Bank's First-Time Home Buyer Survey Reveals That While Homeownership Continues to Be Challenging, Many Americans Are Finding Their Home in Less Than a Year - The Manila Times
Indaptus Therapeutics Initiates Unrestricted Enrollment of - GlobeNewswire
Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 - MSN
Indaptus Therapeutics Founder and Chief Scientific Officer - GlobeNewswire
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 140.5% - Defense World
Cybin (NYSEAMERICAN:CYBN) Shares Down 4.4% - Defense World
Japan Tobacco Inc. (OTCMKTS:JAPAY) Short Interest Update - Defense World
Sei Investments Co. Has $17.72 Million Position in Teradata Co. (NYSE:TDC) - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 9.2% - Defense World
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights - Marketscreener.com
Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term IART Shareholders to Contact the Firm - Business Wire
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
StockNews.com Downgrades Independent Bank (NASDAQ:INDB) to Sell - Defense World
Integrated BioPharma (OTCMKTS:INBP) Trading Down 2.2% - Defense World
Indivior PLC REMINDER – INDV Stockholders Should Contact - GlobeNewswire
IBTX stock hits 52-week high at $60.77 amid robust growth - Investing.com
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit - PR Newswire
Northland Capmk Equities Analysts Cut Earnings Estimates for Indivior PLC (NASDAQ:INDV) - MarketBeat
Holdings of Intelligent Bio Solutions Inc (INBS) are aligned with the stars - SETE News
Upward Trajectory: Intelligent Bio Solutions Inc (INBS) Posts a Gaine, Closing at 2.48 - The Dwinnex
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming DeadlinesINDV - PR Newswire
Financial Health Check: Examining Indivior Plc (INDV)’s Key Ratios - The Dwinnex
Class Action Lawsuit Against Indivior PLC (NASDAQ:INDV) - TipRanks
Ready to Jump After Recent Trade: Indivior Plc (INDV) - SETE News
Indivior PLC Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsINDV - PR Newswire
Intelligent Bio Solutions Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value - GlobeNewswire
Technical analysis of Intelligent Bio Solutions Inc (INBS) stock chart patterns - US Post News
Negative FDA AdCom vote on Ocaliva - The Pharma Letter
The Gross Law Firm Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - PR Newswire
Piper Sandler Reaffirms “Overweight” Rating for Indivior (NASDAQ:INDV) - Defense World
INDV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Indivior PLC (NASDAQ:INDV) Shares Sold by Royal London Asset Management Ltd. - MarketBeat
INVESTOR ALERT: DiCello Levitt LLP Shareholder Class Action - GlobeNewswire
Indivior's (INDV) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Intl Paper Co stock hits 52-week high at $49.25 amid market rally By Investing.com - Investing.com South Africa
In the Green: Indivior Plc (INDV) Closes at 9.62, Up/Down 0.42 from Previous Day - The Dwinnex
INmune Bio stock dips on $13M securities offering - MSN
Indaptus Therapeutics Reports Encouraging New Safety Data - GlobeNewswire
INDP stock touches 52-week low at $1.55 amid market challenges - Investing.com Canada
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Intec Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020 - Marketscreener.com
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):